Reduced Sox9 function promotes heart valve calcification phenotypes in vivo

Circulation Research

Volumn 106, Issue 4, 2010, Pages 712-719

  Peacock, Jacqueline D ^a   Levay, Agata K ^a   Gillaspie, Devin B ^a   Tao, Ge ^a   Lincoln, Joy ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Calcification; Extracellular matrix; Heart valves; Mouse model; Sox9

Indexed keywords

RETINOIC ACID; TRANSCRIPTION FACTOR SOX9;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIFICATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; IN VIVO STUDY; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; VALVULAR HEART DISEASE;

AGE FACTORS; AGING; ANIMALS; ANIMALS, NEWBORN; CALCINOSIS; CALCIUM; CHICK EMBRYO; COLLAGEN TYPE II; DISEASE MODELS, ANIMAL; DOWN-REGULATION; EXTRACELLULAR MATRIX; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENOTYPE; HEART VALVE DISEASES; INFLAMMATION; INTEGRASES; MALE; MICE; MICE, TRANSGENIC; MITRAL VALVE; OSTEOGENESIS; PHENOTYPE; SOX9 TRANSCRIPTION FACTOR; TISSUE CULTURE TECHNIQUES; TRANSFECTION; TRETINOIN; TRICUSPID VALVE;

EID: 77949388887     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.213702     Document Type: Article

References (63)

1. Stewart B, Siscovick D, Lind B, Gardin J, Gottdiener J, Smith V, Kitzman D, Otto C. Clinical factors associated with calcific aortic valvular disease. J Am Coll Cardiol. 1997;29:630-634.
2. Otto CM. Calcific aortic stenosis-time to look more closely at the valve. N Engl J Med. 2008;359:1395-1398.
3. Hinton RB Jr, Lincoln J, Deutsch GH, Osinska H, Manning PB, Benson DW, Yutzey KE. Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circ Res. 2006;98:1431-1438.
4. Lincoln J, Lange AW, Yutzey KE. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol. 2006;294:292-302.
5. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001;104:2525-2532.
6. Schoen FJ. Cardiac valves and valvular pathology: Update on function, disease, repair, and replacement. Cardiovasc Pathol. 2005;14:189-194.
7. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184.
8. O'Brien KD. Pathogenesis of calcific aortic valvular disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol. 2006;26:1721-1728.
9. Mohler ER III. Mechanisms of aortic valve calcification. Am J Cardiol. 2004;94:1396-1402.
10. Rajamannan NM, Nealis TB, Subramaniam M, Pandya S, Stock SR, Ignatiev CI, Sebo TJ, Rosengart TK, Edwards WD, McCarthy PM, Bonow RO, Spelsberg TC. Calcified rheumatic valve neoangiogenesis is associated with vascular endothelial growth factor expression and osteoblast-like bone formation. Circulation. 2005;111:3296-3301.
11. Caira F, Stock S, Gleason T, McGee E, Huang J, Bonow R, Spelsberg T, McCarthy P, Rahimtoola S, Rajamannan N. Human degenerative valvular disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
12. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747-754.
13. Yoshioka M, Yuasa S, Matsumura K, Kimura K, Shiomi T, Kimura N, Shukunami C, Okada Y, Mukai M, Shin H, Yozu R, Sata M, Ogawa S, Hiraki Y, Fukuda K. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med. 2006;12:1151-1159.
14. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valvular disease. Nature. 2005;437:270-274.
15. Garg V. Insights into the genetic basis of congenital heart disease. Cell Mol Life Sci. 2006;63:1141-1148.
16. Person AD, Klewer SE, Runyan RB. Cell biology of cardiac cushion development. Int Rev Cytol. 2005;243:287-335.
17. de Lange FJ, Moorman AF, Anderson RH, Männer J, Soufan AT, de Gier-de Vries C, Schneider MD, Webb S, van den Hoff MJ, Christoffels VM. Lineage and morphogenetic analysis of the cardiac valves. Circ Res. 2004;95:645-654.
18. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004;95:459-470.
19. Lincoln J, Alfieri CM, Yutzey KE. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dyn. 2004;230:239-250.
20. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol. 2007;305:120-132.
21. Levay AK, Peacock JD, Lu Y, Koch M, Hinton RB Jr, Kadler KE, Lincoln J. Scleraxis is required for cell lineage differentiation and extracellular matrix remodeling during murine heart valve formation in vivo. Circ Res. 2008;103:948-956.
22. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation; 10.1038/8792. Nat Genet. 1999;22:85-89.
23. Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization. Proc Natl Acad Sci USA. 2001;98:6698-6703.
24. Mori-Akiyama Y, Akiyama H, Rowitch DH, de Crombrugghe B. Sox9 is required for determination of the chondrogenic cell lineage in the cranial neural crest. Proc Natl Acad Sci USA. 2003;100:9360-9365.
25. Zhou G, Zheng Q, Engin F, Munivez E, Chen Y, Sebald E, Krakow D, Lee B. Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci USA. 2006;103:19004-19009.
26. Lincoln J, Alfieri C, Yutzey K. BMP and FGF regulatory pathways control cell lineage diversification of heart valve precursor cells. Dev Biol. 2006;292:290-302.
27. Yoon BS, Lyons KM. Multiple functions of BMPs in chondrogenesis. J Cell Biochem. 2004;93:93-103.
28. Hoffman LM, Weston AD, Underhill TM. Molecular mechanisms regulating chondroblast differentiation. J Bone Joint Surg Am. 2003;85:124-132.
29. Sekiya I, Koopman P, Tsuji K, Mertin S, Harley V, Yamada Y, Shinomiya K, Niguji A, Noda M. Transcriptional suppression of Sox9 expression in chondrocytes by retinoic acid. J Cell Biochem. 2001;81:71-78.
30. Iwamoto M, Shapiro IM, Yagami K, Boskey AL, Leboy PS, Adams SL, Pacifici M. Retinoic acid induces rapid mineralization and expression of mineralization-related genes in chondrocytes. Exp Cell Res. 1993;207:413-420.
31. Jimenez MJG, Balbin M, Alvarez J, Komori T, Bianco P, Holmbeck K, Birkedal-Hansen H, Lopez JM, Lopez-Otin C. A regulatory cascade involving retinoic acid, Cbfa1, and matrix metalloproteinases is coupled to the development of a process of perichondrial invasion and osteogenic differentiation during bone formation. J Cell Biol. 2001;155:1333-1344.
32. Kist R, Schrewe H, Balling R, Scherer G. Conditional inactivation of Sox9: a mouse model for campomelic dysplasia. Genesis. 2002;32:121-123.
33. Ovchinnikov DA, Deng JM, Ogunrinu G, Behringer RR. Col2a1-directed expression of cre recombinase in differentiating chondrocytes in transgenic mice. Genesis. 2000;26:145-146.
34. Peacock JD, Lu Y, Koch M, Kadler KE, Lincoln J. Temporal and spatial expression of collagens during murine atrioventricular heart valve development and maintenance. Dev Dyn. 2008;237:3051-3058.
35. Nakamura T, Colbert MC, Robbins J. Neural crest cells retain multipo-tential characteristics in the developing valves and label the cardiac conduction system. Circ Res. 2006;98:1547-1554.
36. Schoen FJ. Evolving concepts of cardiac valve dynamics: the continuum of development, functional structure, pathobiology, and tissue engineering. Circulation. 2008;118:1864-1880.
37. Yang X, Fullerton DA, Su X, Ao L, Cleveland JC Jr, Meng X. Pro-osteogenic phenotype of human aortic valve interstitial cells is associated with higher levels of toll-like receptors 2 and 4 and enhanced expression of bone morphogenetic protein 2. J Am Coll Cardiol. 2009;53:491-500.
38. Pohjolainen V, Taskinen P, Soini Y, Rysä J, Ilves M, Juvonen T, Ruskoaho H, Leskinen H, Satta J. Noncollagenous bone matrix proteins as a part of calcific aortic valvular disease regulation. Hum Pathol. 2008;39:1695-1701.
39. Hadian M, Corcoran BM, Han RI, Grossmann JG, Bradshaw JP. Collagen organization in canine myxomatous mitral valvular disease: an X-ray diffraction study. Biophys J. 2007;93:2472-2476.
40. Yeghiazaryan K, Skowasch D, Bauriedel G, Schild H, Golubnitschaja O. Could activated tissue remodeling be considered as early marker for progressive valve degeneration? Comparative analysis of checkpoint and ECM remodeling gene expression in native degenerating aortic valves and after bioprosthetic replacement. Amino Acids. 2007;32:109-114.
41. Kaden JJ, Bickelhaupt S, Grobholz R, Haase KK, Sarikoc A, Kilic R, Brueckmann M, Lang S, Zahn I, Vahl C, Hagl S, Dempfle C, Borggrefe M. Receptor activator of nuclear factor KB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol. 2004;36:57-66.
42. Alexopoulos A, Bravou V, Peroukides S, Kaklamanis L, Varakis J, Alexopoulos D, Papadaki H. Bone regulatory factors NFATc1 and osterix in human calcific aortic valves. Int J Cardiol. In press.
43. Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999;8: 254-260.
44. Schroeder TM, Jensen ED, Westendorf JJ. Runx2: a master organizer of gene transcription in developing and maturing osteoblasts. Birth Defects Res C Embryo Today. 2005;75:213-225.
45. Mohler ER III, Gannon F, Reynolds C, Zimmerman R, Keane MG, Kaplan FS. Bone formation and inflammation in cardiac valves. Circulation. 2001; 103:1522-1528.
46. Akat K, Borggrefe M, Kaden JJ. Aortic valve calcification-basic science to clinical practice. Heart. 2008;95:616-623.
47. Ghaisas NK, Foley JB, O'Briain DS, Crean P, Kelleher D, Walsh M. Adhesion molecules in nonrheumatic aortic valvular disease: endothelial expression, serum levels and effects of valve replacement. J Am Coll Cardiol. 2000;36:2257-2262.
48. Lobb R, Chi-Rosso G, Leone D, Rosa M, Newman B, Luhowskyj S, Osborn L, Schiffer S, Benjamin c, Dougas I, Hession C, Chow P. Expression and functional characterization of a soluble form of vascular cell adhesion molecule 1. Biochem Biophys Res Commun. 1991;178: 1498-1504.
49. Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK, Cartwright N. Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. J Endocrinol. 2007;193:323-330.
50. Meng X, Ao L, Song Y, Babu A, Yang X, Wang M, Weyant MJ, Dinarello CA, Cleveland JC Jr, Fullerton DA. Expression of functional toll-like receptors 2 and 4 in human aortic valve interstitial cells: Potential roles in aortic valve inflammation and stenosis. Am J Physiol Cell Physiol. 2008;294:C29-C35.
51. Kuhn C, Mason RJ. Immunolocalization of SPARC, tenascin, and throm-bospondin in pulmonary fibrosis. Am J Pathol. 1995;147:1759-1769.
52. Herpel E, Pritsch M, Koch A, Dengler TJ, Schirmacher P, Schnabel PA. Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Histopathology. 2006;48:736-747.
53. Aikawa E, Aikawa M, Libby P, Figueiredo J, Rusanescu G, Iwamoto Y, Fukuda D, Kohler RH, Shi G, Jaffer FA, Weissleder R. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation. 2009;119:1785-1794.
54. Bridgewater LC, Walker MD, Miller GC, Ellison TA, Holsinger LD, Potter JL, Jackson TL, Chen RK, Winkel VL, Zhang Z, McKinney S, de Crombrugghe B. Adjacent DNA sequences modulate Sox9 transcriptional activation at paired sox sites in three chondrocyte-specific enhancer elements. Nucleic Acids Res. 2003;31:1541-1553.
55. Akiyama H, Chaboissier M, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813-2828.
56. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114: 2065-2069.
57. Drolet M, Roussel E, Deshaies Y, Couet J, Arsenault M. A high Fat/High carbohydrate diet induces aortic valvular disease in C57BL/6J mice. J Am Coll Cardiol. 2006;47:850-855.
58. Cawley PJ, Otto CM. Prevention of calcific aortic valve stenosis\fact or fiction? Ann Med. 2009;41:100.
59. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA. The Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352:2389-2397.
60. Rossebø AB, Pedersen TR, Allen C, Boman K, Chambers J, Egstrup K, Gerdts E, Gohlke-Bärwolf C, Holme I, Kesäniemi VAY, Malbecq W, Nienaber C, Ray S, Skjærpe T, Wachtell K, Willenheimer R. Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study. Am J Cardiol. 2007;99:970-973.
61. Kafienah W, Mistry S, Perry MJ, Politopoulou G, Hollander AP. Pharmacological regulation of adult stem cells: chondrogenesis can be induced using a synthetic inhibitor of the retinoic acid receptor. Stem Cells. 2007;25:2460-2468.
62. Lin C, Chen C, Lin T, Tung JC, Wang S. Anti-inflammation activity of fruit essential oil from cinnamomum insularimontanum hayata. Bioresour Technol. 2008;99:8783-8787.
63. Nagpal S, Lu J, Boehm MF. Vitamin D analogs: mechanism of action and therapeutic applications. Curr Med Chem. 2001;8:1661-1679.